# Executive Summary — Multivalent Nanoparticle-pMHC-II EoE Tolerance Platform

**Paper:** *Rational design of multivalent nanoparticle-pMHC-II immunotherapies for food allergen tolerance induction in eosinophilic esophagitis.*
**Status:** bioRxiv-style preprint; citizen-science project by an EoE patient-researcher (PhD immunology) with computational support during a one-week hackathon. **All results are computational (in-silico); epitopes and structures are predictions/model estimates and have not been made or tested in the lab.**

## What the paper does
It presents a rational-design platform for multivalent nanoparticle-pMHC-II immunotherapies aimed at inducing durable, antigen-specific tolerance to the three most common EoE food triggers — dairy, wheat, and soy — rather than suppressing inflammation indefinitely. It integrates computational epitope discovery, high-confidence structural modeling, a multivalent nanoparticle architecture, three therapeutic formats, and a transparent, costed preclinical roadmap with explicit regulatory gates.

## The three modalities
- **Soluble single-chain pMHC-II** (449 aa) — DRA–linker–DRB–linker–peptide construct.
- **Multivalent nanoparticle-pMHC** — 20 nm Fe₃O₄ core, 5 pMHC copies, 5.8 nm spacing, ~24× avidity gain; the tolerogenic scaffold, using standard iron-oxide conjugation chemistry.
- **Tetramer pMHC-II** (469 aa).

## Key numbers (all traceable to artifacts/public sources)
- Triggers addressed: milk (>60% of patients), wheat (>40%), soy (>30%).
- Epitope pipeline: 47 candidate epitopes → 12 strong HLA-DRB1*07:01 binders → three leads — dairy **FAQTQSLVY**, wheat **HNVVHAIIL**, soy **FVVNATSNL** — with IC₅₀ **16.78–50.31 nM**.
- Precursor-vs-mature detail: the best dairy epitope (from the β-casein precursor) binds at 16.78 nM vs 1,535.53 nM for the mature form — a ~92-fold affinity difference that drove frame selection.
- Structural validation (ESMFold2-Fast): complex ipTM **0.872–0.896**, single-chain pLDDT **0.824**; all peptides canonical in the MHC-II groove (15/15 residues, 59–64 of 90 core contacts).
- Development: 18–24 month preclinical roadmap, **$275–457k** across five phases.

## Why it matters
It aims at the durable-tolerance gap that no approved EoE therapy fills, packages three complementary delivery formats with a manufacturable nanoparticle scaffold, and pairs the science with a partner-ready regulatory and development plan. It also demonstrates a citizen-science model — a patient-researcher plus AI tools producing a rigorous, transparent drug-design package in a compressed timeframe.

## Honest verdict and what remains
The framing matches the evidence: epitopes and structures are computational predictions and model estimates, and nothing has been made or functionally tested. The designs cover a single common HLA type (DRB1*07:01); multi-HLA expansion (DQ2, DQ8, DQ5, DR4) is flagged as an early, FDA-relevant requirement to justify population coverage and support an orphan/breakthrough pathway. Long-term iron-oxide safety and Tr1-induction efficacy are named open questions the preclinical roadmap is built to answer.